Skip to main content
main-content

Lung cancer

Lung cancer

18-07-2019 | Oncology | News | Article

Genomic markers of brain metastasis risk identified in NSCLC

Researchers have identified key genomic alterations in brain metastases matched to primary non-small-cell lung cancer that could serve as prognostic markers and potential therapeutic targets.

16-07-2019 | Oncology | News | Article

Phase I data support dual VEGFR2, PD-1 inhibition

Phase I study data suggest that ramucirumab plus pembrolizumab is a feasible treatment option for patients with previously treated advanced non-small-cell lung cancer, urothelial carcinoma, and gastric or gastroesophageal junction adenocarcinoma.

12-07-2019 | Oncology | News | Article

Low-dose CT provides superior screening for lung cancer death in high-risk smokers

Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.

09-07-2019 | Oncology | News | Article

Vemurafenib monotherapy has potential for BRAF-mutated NSCLC

Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.

08-07-2019 | Oncology | News | Article

Expansion of USPSTF lung screening criteria warranted

Results from two studies suggest that the current US Preventive Services Task Force lung cancer screening criteria may exclude certain individuals who could benefit from screening.

03-07-2019 | Oncology | News | Article

Steroid indication plays key role in link to poor immunotherapy outcome

Poor outcomes among patients with non-small-cell lung cancer who receive corticosteroids prior to immunotherapy are driven by the use of steroids for palliative oncologic symptom management, study findings indicate.

28-06-2019 | Oncology | News | Article

Checkpoint inhibitor rechallenge feasible after irAE-related discontinuation

Two studies point to the feasibility of resuming immune checkpoint inhibitors in patients who discontinue treatment due to immune-related adverse events.

27-06-2019 | Oncology | News | Article

Chest radiation increases cardiac risk in NSCLC patients

Patients with locally advanced non-small-cell lung cancer have a high risk for major adverse cardiac events after radiotherapy that may warrant a reduction in cardiac radiation dose, study findings indicate.

25-06-2019 | Oncology | News | Article

Pembrolizumab approved in USA for metastatic SCLC

Click through for the details of this FDA decision

24-06-2019 | Oncology | News | Article

Adding chemotherapy to gefitinib improves EGFR-mutated NSCLC outcomes

Supplementing the EGFR–tyrosine kinase inhibitor gefitinib with pemetrexed and carboplatin doubles progression-free survival in patients with advanced, chemotherapy-naïve non-small-cell lung cancer harboring activating EGFR mutations, according to phase III results.

21-06-2019 | Oncology | News | Article

Neoadjuvant immunotherapy shows promise for resectable NSCLC

Neoadjuvant immunotherapy produces encouraging major pathologic response rates among patients with resectable non-small-cell lung cancer, show data presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

20-06-2019 | Oncology | News | Article

Maintenance bevacizumab–pemetrexed improves PFS of nonsquamous NSCLC patients

Two studies presented at the 2019 ASCO Annual Meeting show a significant progression-free survival, but not overall survival, benefit with the addition of pemetrexed to bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer.

19-06-2019 | Oncology | News | Article

No survival boost for advanced NSCLC with metformin

Metformin does not improve progression-free survival for patients without diabetes who require chemoradiotherapy for stage IIIA or IIIB non-small-cell lung cancer, suggests research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

18-06-2019 | Oncology | News | Article

Broadening clinical trial inclusion criteria doubles number of eligible NSCLC patients

Using expanded criteria for clinical trial inclusion could lead to nearly twice as many patients with advanced non-small-cell lung cancer being eligible for participation compared with traditional criteria, participants at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, heard.

14-06-2019 | Oncology | News | Article

TAK-788 shows activity against NSCLC with EGFR exon 20 insertions

The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.

13-06-2019 | Oncology | News | Article

BLU-667 active against RET fusion-positive advanced NSCLC

Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.

11-06-2019 | Oncology | News | Article

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

07-06-2019 | Oncology | News | Article

Prolonged survival possible with pembrolizumab in advanced NSCLC

Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.

07-06-2019 | Oncology | News | Article

Lurbinectedin shows potential for second-line SCLC treatment

Lurbinectedin monotherapy is active in the second-line treatment of both platinum-sensitive and -resistant small-cell lung cancer, according to phase II results presented at the 2019 ASCO Annual Meeting.

05-06-2019 | Oncology | Main feed | News

EGFR–cMET bispecific antibody shows efficacy in NSCLC patients with high unmet needs

Preliminary findings for a first-in-human study of JNJ-372 – a bispecific IgG antibody targeting both the EGFR and cMET receptors – have been reported at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

Image Credits